| All patients (n = 238) | Patients with x-rays available (n = 125) | Progressors 10 years (n = 74) | Non-progressors 10 years (n = 51) | |
| Female (%) | 73.5 | 75.2 | 82.4* | 64.7 |
| Mean (SD) disease duration, years | 2.3 (1.2) | 2.2 (1.2) | 2.2 (1.2) | 2.1 (1.1) |
| Mean (SD) age, years | 51.9 (13.0) | 50.7 (12.7) | 50.9 (12.5) | 50.4 (13.2) |
| Anti-CCP positive (%) | 60.5 | 59.2 | 74.7* | 35.3 |
| IgA RF positive (%) | 37.8 | 34.5 | 45.9* | 17.6 |
| IgM RF positive (%) | 47.9 | 44.0 | 59.5* | 21.6 |
| Median (IQR) CRP, mg/l | 5.3 (1.7–13.8) | 4.9 (1.7–13.8) | 6.1* (2.9–15.5) | 2.9 (1.35–8.1) |
| Median (IQR) ESR, mm/h | 20.5 (10.0–36.0) | 20.0 (10.0–36.0) | 25.5* (16.0–44.5) | 13.0 (7.0–26.0) |
| Median (IQR) Anti-CCP, U/ml | 58.9 (4.0–247.2) | 46.6 (4.0–247.2) | 109.6* (25.3–251.0) | 6.1 (1.8–78.0) |
| Mean (SD) HAQ score | 0.9 (0.6) | 0.9 (0.6) | 0.9 (0.6) | 0.8 (0.6) |
| Erosive disease (%) | 55.2† | 54.4 | 71.6* | 29.4 |
| Mean (SD) progression rate at baseline (SHS units/year) | 2.9 (4.6)† | 3.1 (5.0) | 4.7* (5.7) | 0.9 (2.3) |
| DMARD use (%) | 52.1 | 52.8 | 55.4 | 49.0 |
*Significant (p<0.05) difference between patients with and without radiographic progression.
†n = 163.
Anti-CCP, antibodies to cyclic citrullinated peptide; IgA RF, immunoglobulin A rheumatoid factor; IgM RF, immunoglobulin M rheumatoid factor; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; DMARD, Disease modifying anti rheumatic drugs; IQR, Inter Quartile Range; SHS, van der Heijde modified Sharp score.